Related Articles
Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs
Mechanism underlying the transient increase of serum iron during FOLFOX/FOLFIRI therapy
Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase‑2 in patients with gastric cancer
Effects of cytokine‑induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery
Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer